KIT and gastrointestinal stromal tumor: In a prospective multicenter phase II study involving patients with unresectable, KIT-positive GIST that had progressed on treatment with imatinib and sunitinib, the median PFS and OS times were 5.2 and 11.6 months, respectively, while the one- and two-year survival rates were 50 and 29%, respectively (27).